Evotec AG today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-extends-integrated-drug-discovery-alliance-with-genentech-5364
Evotec AG reports results of first quarter 2016
Evotec AG today reported financial results and corporate updates for the first quarter of 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-quarter-2016-5362
Evotec to report First Quarter 2016 Results on 10 May 2016
Hamburg, Germany – 03 May 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2016 on Tuesday, 10 May 2016. The Company is going to hold a … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-report-first-quarter-2016-results-on-10-may-2016-5360
Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics
Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-exscientia-announce-partnership-to-discover-bispecific-small-molecule-immuno-oncology-therapeutics-5356
Evotec and Pierre Fabre sign multi-year compound management agreement
Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-pierre-fabre-sign-multi-year-compound-management-agreement-5354
Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH'
Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-spins-off-auto-immune-disease-company-as-topas-therapeutics-gmbh-5350
Evotec FY 2015: Excellent execution meets first-in-class innovation
Evotec AG today announced its financial results for the fiscal year ended 31 December 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fy-2015-excellent-execution-meets-first-in-class-innovation-5352
Evotec AG: Fiscal year 2015 results presentation on 22 March 2016
Hamburg, Germany – 15 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for 2015 on Tuesday, 22 March 2016. The Company is going to hold a conference call to … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-fiscal-year-2015-results-presentation-on-22-march-2016-5348
Evotec achieves milestone in collaboration with Padlock Therapeutics
Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. („Padlock“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-collaboration-with-padlock-therapeutics-5346
Evotec to present at IR conference
Hamburg, Germany – 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-present-at-ir-conference-5344